Budesonide oral suspension effective against pediatric EoE

Twice-daily budesonide oral suspension, or BOS, improved outcomes in pediatric patients with eosinophilic esophagitis, according to research presented at this year’s virtual American Academy of Allergy, Asthma and Immunology Annual Meeting.“In terms of safety assessments, BOS 2 mg twice daily was, overall, well-tolerated in this pediatric cohort,” Sandeep K. Gupta, MD, of the section of pediatric gastroenterology, hepatology and nutrition at Indiana University School of Medicine and Riley Hospital for Children at Indiana University Health, said during the presentation.GuptaRead More

Share on facebook
Share on twitter
Share on linkedin